search
Back to results

To Study and Evaluate the Effectiveness of Treatment by Percutaneous Electrical NeuroStimulation (PENS) for Post-operative Pain in Cesarean Section Patients Using Primary Relief v 2.0 (POPS)

Primary Purpose

Cesarean Section; Dehiscence

Status
Unknown status
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Primary Relief v 2.0
Paracetamol
Sponsored by
DyAnsys, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cesarean Section; Dehiscence

Eligibility Criteria

22 Years - 35 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age range between 22 - 35 years
  2. Patient willing to undergo C-section surgery
  3. Patient having pains after one hour of post C-Section surgery
  4. Patients who is conscious and oriented for device installation after anesthetic effect
  5. Patient who completed required clinical and biochemical investigations as deemed necessary by the gynecologist after post C - section surgery.
  6. No previous poor obstetrical outcome
  7. No experience in Han's Acupoint nerve stimulator and TENS for other reasons.
  8. Term pregnancy (> 37 weeks of gestation).
  9. Understands and is willing to participate in the clinical study and can comply with study procedures.
  10. Normal cognitive and communicative ability as judged by clinical assessment and ability to complete self-reported questionnaires.

Exclusion Criteria:

  1. Had been diagnosed with other diseases such as preoperative presence of maternal mental, neurological disease, affecting evaluation of pains and disease condition.
  2. Had combined with gestational hypertension, gestational diabetes, gestational thyroid disease.
  3. Had taken analgesic drugs
  4. Had used diazepam, piperazine hydrochloride or other sedative, analgesic drugs in the stage of labor.
  5. Were overweight or low pregnancy weight, Body mass index (< 18.5 or >25 kg/m2).
  6. Patients who are not agreeing to receive painless labor and not sign the informed consent form.
  7. Neonatal problem requiring immediate separation from the mother for medical care or NICU admittance.
  8. Severe placental abruption.
  9. Hydrops (accumulation of fluid or edema in fetus body tissue and cavities) if secondary to anemia or heart failure.
  10. Known twin to twin transfusion syndrome (TTS).
  11. Congenital anomalies that may hamper the procedure (gastroschisis, amphalacele, spina bifida).
  12. Home birth.
  13. Severe mental health problem
  14. Hearing impairment.
  15. Legal abortion
  16. Twin pregnancy
  17. Instrumental birth
  18. Uterine anomalies with contraindication for vaginal birth. Eg: previous opening of uterine cavity, myomectomy, congenital abnormalities.
  19. Placenta anomalies.
  20. Placenta praevia, suspected acreta, increta, percreta especially after previous caesarean.
  21. Fetal abnormalities, growth restriction.
  22. Maternal complication with surgery.
  23. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening; or subject or physician anticipates use of any of these therapies by the subject during the course of the study
  24. Previous participation in the Treatment Phase of this Protocol
  25. Malignant disease not in remission for five years or more that has been medically or surgically treated without evidence of metastases
  26. Presence of one or more medical conditions, as determined by medical history, which seriously compromises the subject's ability to complete the study, including history of poor adherence with medical treatment, unstable pain intensity or pain medications 6 weeks prior to the study, renal, hepatic, hematologic, active auto-immune or immune diseases that, in the opinion of the Investigator, would make the subject an inappropriate candidate for this study: a) One or more abnormal blood biochemistry analyte result that is ≥ 3 times that of the upper limit of the normal range
  27. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV)
  28. American Heart Association (AHA) Class III and IV congestive heart failure (CHF), as defined by the following criteria: a) Class III: Symptoms with moderate exertion b) Class IV: Symptoms at rest or c) Cardiac pacemakers.
  29. Subjects with a diagnosis of psychiatric disorders such as major depressive disorder, bipolar disorder, obsessive compulsive disorder, generalized anxiety, dysthymia or suicidality/suicide ideation
  30. Subjects not willing to undergo treatment before discharge from the hospital.

Sites / Locations

  • ClinicRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Primary Relief v 2.0 Device

Paracetamol

Arm Description

The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.

A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously

Outcomes

Primary Outcome Measures

assessing the effects of PENS therapy in Postoperative period of Lower Segment Caesarean Section pain using VAS score.
To assess the effects of PENS therapy in Post-Operative period of Lower Segment Caesarean Section pain using the Visual Analogue Scale measurement. The level of pain is calculated from the VAS (Visual Analogue Scale) before the device is installed and assessed after 2 hours of the device activation. The pain level should be decreased when assessing after 2 hours of device installation. The score should be below 5. where 0 being no pain, 5 being moderate and 10 being maximum pain.

Secondary Outcome Measures

Evaluate the impact of this treatment in terms of Quality Of Life
whether treatment can negate the need for more complex surgical treatments and/or reduce the need for drug treatment. Change in quality of life will be measured using the Evaluation form measurement.

Full Information

First Posted
January 27, 2019
Last Updated
February 1, 2019
Sponsor
DyAnsys, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03829774
Brief Title
To Study and Evaluate the Effectiveness of Treatment by Percutaneous Electrical NeuroStimulation (PENS) for Post-operative Pain in Cesarean Section Patients Using Primary Relief v 2.0
Acronym
POPS
Official Title
To Study and Evaluate the Effectiveness of Treatment by Percutaneous Electrical NeuroStimulation (PENS) for Post-operative Pain in Cesarean Section Patients Using Primary Relief v 2.0
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 2, 2019 (Actual)
Primary Completion Date
March 2019 (Anticipated)
Study Completion Date
July 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
DyAnsys, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To study and evaluate the Effectiveness of Treatment by Percutaneous Electrical NeuroStimulation (PENS) for post-operative pain in Cesarean Section patients using First Relief

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cesarean Section; Dehiscence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
22 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Primary Relief v 2.0 Device
Arm Type
Experimental
Arm Description
The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
Arm Title
Paracetamol
Arm Type
Placebo Comparator
Arm Description
A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
Intervention Type
Device
Intervention Name(s)
Primary Relief v 2.0
Other Intervention Name(s)
Percutaeneous Nerve Field Stimulator Neurostimulator
Intervention Description
The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
Intervention Type
Drug
Intervention Name(s)
Paracetamol
Other Intervention Name(s)
Standard Drug Treatment for Postoperative pain
Intervention Description
A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
Primary Outcome Measure Information:
Title
assessing the effects of PENS therapy in Postoperative period of Lower Segment Caesarean Section pain using VAS score.
Description
To assess the effects of PENS therapy in Post-Operative period of Lower Segment Caesarean Section pain using the Visual Analogue Scale measurement. The level of pain is calculated from the VAS (Visual Analogue Scale) before the device is installed and assessed after 2 hours of the device activation. The pain level should be decreased when assessing after 2 hours of device installation. The score should be below 5. where 0 being no pain, 5 being moderate and 10 being maximum pain.
Time Frame
2 hours of device activation
Secondary Outcome Measure Information:
Title
Evaluate the impact of this treatment in terms of Quality Of Life
Description
whether treatment can negate the need for more complex surgical treatments and/or reduce the need for drug treatment. Change in quality of life will be measured using the Evaluation form measurement.
Time Frame
2nd day

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Pregnant Women willing to undergo C-Section
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age range between 22 - 35 years Patient willing to undergo C-section surgery Patient having pains after one hour of post C-Section surgery Patients who is conscious and oriented for device installation after anesthetic effect Patient who completed required clinical and biochemical investigations as deemed necessary by the gynecologist after post C - section surgery. No previous poor obstetrical outcome No experience in Han's Acupoint nerve stimulator and TENS for other reasons. Term pregnancy (> 37 weeks of gestation). Understands and is willing to participate in the clinical study and can comply with study procedures. Normal cognitive and communicative ability as judged by clinical assessment and ability to complete self-reported questionnaires. Exclusion Criteria: Had been diagnosed with other diseases such as preoperative presence of maternal mental, neurological disease, affecting evaluation of pains and disease condition. Had combined with gestational hypertension, gestational diabetes, gestational thyroid disease. Had taken analgesic drugs Had used diazepam, piperazine hydrochloride or other sedative, analgesic drugs in the stage of labor. Were overweight or low pregnancy weight, Body mass index (< 18.5 or >25 kg/m2). Patients who are not agreeing to receive painless labor and not sign the informed consent form. Neonatal problem requiring immediate separation from the mother for medical care or NICU admittance. Severe placental abruption. Hydrops (accumulation of fluid or edema in fetus body tissue and cavities) if secondary to anemia or heart failure. Known twin to twin transfusion syndrome (TTS). Congenital anomalies that may hamper the procedure (gastroschisis, amphalacele, spina bifida). Home birth. Severe mental health problem Hearing impairment. Legal abortion Twin pregnancy Instrumental birth Uterine anomalies with contraindication for vaginal birth. Eg: previous opening of uterine cavity, myomectomy, congenital abnormalities. Placenta anomalies. Placenta praevia, suspected acreta, increta, percreta especially after previous caesarean. Fetal abnormalities, growth restriction. Maternal complication with surgery. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening; or subject or physician anticipates use of any of these therapies by the subject during the course of the study Previous participation in the Treatment Phase of this Protocol Malignant disease not in remission for five years or more that has been medically or surgically treated without evidence of metastases Presence of one or more medical conditions, as determined by medical history, which seriously compromises the subject's ability to complete the study, including history of poor adherence with medical treatment, unstable pain intensity or pain medications 6 weeks prior to the study, renal, hepatic, hematologic, active auto-immune or immune diseases that, in the opinion of the Investigator, would make the subject an inappropriate candidate for this study: a) One or more abnormal blood biochemistry analyte result that is ≥ 3 times that of the upper limit of the normal range Known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV) American Heart Association (AHA) Class III and IV congestive heart failure (CHF), as defined by the following criteria: a) Class III: Symptoms with moderate exertion b) Class IV: Symptoms at rest or c) Cardiac pacemakers. Subjects with a diagnosis of psychiatric disorders such as major depressive disorder, bipolar disorder, obsessive compulsive disorder, generalized anxiety, dysthymia or suicidality/suicide ideation Subjects not willing to undergo treatment before discharge from the hospital.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Balachandran V, MD
Phone
+91 9946452707
Email
v.balachandran@dyansys.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hariharan A, B.Tech
Phone
+91 8124147672
Email
a.hariharan@dyansys.com
Facility Information:
Facility Name
Clinic
City
Warangal
State/Province
Telangana
ZIP/Postal Code
506002
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Balachandran V, MD
Phone
9496452707
Email
v.balachandaran@dyansys.com
First Name & Middle Initial & Last Name & Degree
Robin M, GNM
Phone
8722627172

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
32871021
Citation
Zimpel SA, Torloni MR, Porfirio GJ, Flumignan RL, da Silva EM. Complementary and alternative therapies for post-caesarean pain. Cochrane Database Syst Rev. 2020 Sep 1;9(9):CD011216. doi: 10.1002/14651858.CD011216.pub2.
Results Reference
derived

Learn more about this trial

To Study and Evaluate the Effectiveness of Treatment by Percutaneous Electrical NeuroStimulation (PENS) for Post-operative Pain in Cesarean Section Patients Using Primary Relief v 2.0

We'll reach out to this number within 24 hrs